

LG Chem & TransThera Bio to work on chronic inflammatory conditions

18 August 2020 | News

TT-01025 is expected to enter Phase I trial in early 2021 in the US



South Korean firm LG Chem Life Sciences, a division of LG Chem, and TransThera Biosciences Co. Ltd., a clinical-stage biotechnology company based in Nanjing, China, have announced that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera's TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promising efficacy in pre-clinical investigation in non-alcoholic steatohepatitis (NASH).

TT-01025 is expected to enter Phase I trial in early 2021 in the US.

Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

TransThera will receive upfront payment as well as development and sales milestone payments, totaling up to \$350M, plus tiered royalties on the annual net sales. LG Chem will be responsible for the further development, manufacturing and commercialization of TT-01025.